|
Angosto-Bazarra D, Molina-Lopez C, Pelegrin P. Physiological and pathophysiological functions of NLRP6: pro- and anti-inflammatory roles. Commun Biol. 2022 Jun 1;5(1):524. doi: 10.1038/s42003-022-03491-w. PubMed PMID: 35650327; PubMed Central PMCID: PMC9160023.
AÑO: 2022; IF: 6.548
|
35650327
|
Garcia-Villalba J, Hurtado-Navarro L, Penin-Franch A, Molina-Lopez C, Martinez-Alarcon L, Angosto-Bazarra D, Baroja-Mazo A, Pelegrin P. Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity. Front Immunol. 2022 May 18;13:894470. doi: 10.3389/fimmu.2022.894470. eCollection 2022. PubMed PMID: 35663992; PubMed Central PMCID: PMC9161710.
AÑO: 2022; IF: 7.3
|
|
Weber ANR, Tapia-Abellan A, Liu X, Dickhofer S, Arostegui JI, Pelegrin P, Welzel T, Kuemmerle-Deschner JB. Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. Rheumatology (Oxford). 2022 Oct 6;61(10):e299-e313. doi: 10.1093/rheumatology/keac273. No abstract available. PubMed PMID: 35579347.
AÑO: 2022; IF: 5.5
|
|
Tapiz I Reula AJ, Cochino AV, Martins AL, Angosto-Bazarra D, de Landazuri IO, Mensa-Vilaro A, Cabral M, Baroja-Mazo A, Banos MC, Lobato-Salinas Z, Fabregat V, Plaza S, Yague J, Casals F, Oliva B, Figueiredo AE, Pelegrin P, Arostegui JI. Characterization of Novel Pathogenic Variants Leading to Caspase-8 Cleavage-Resistant RIPK1-Induced Autoinflammatory Syndrome. J Clin Immunol. 2022 Oct;42(7):1421-1432. doi: 10.1007/s10875-022-01298-2. Epub 2022 Jun 18. Erratum In: J Clin Immunol. 2022 Jul 8;: PubMed PMID: 35716229; PubMed Central PMCID: PMC9674708.
AÑO: 2022; IF: 9.1
|
|
Lambris JD, Rosenthal A, Pelegrin P, Tremblay ME, Chen P. The future of neuroimmunology research for CNS disease therapeutics. Trends Pharmacol Sci. 2022 Aug;43(8):611-614. doi: 10.1016/j.tips.2022.06.003. No abstract available. PubMed PMID: 35839748.
AÑO: 2022; IF: 13.8
|